Clonogenic assays with specific BH3 mimetics revealed that ISCs require BCL-2 activity solely during transformation and that this dependence is lost quickly after, while MCL1 inhibition does not affect ISC clonogenicity and BCL-XL is essential for ISC survival throughout CRC progression. The gene discussed is BCL2L1; the disease is colorectal carcinoma.